Cargando…
Factors targeting MED12 to drive tumorigenesis?
Mediator Complex Subunit 12 (MED12) is part of the transcriptional preinitiation machinery. Mutations of its gene predominantly occur in two types of highly frequent benign tumors, uterine leiomyomas and fibroadenomas of the breast, where they apparently act as driver mutations. Nevertheless, their...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325618/ https://www.ncbi.nlm.nih.gov/pubmed/30647905 http://dx.doi.org/10.12688/f1000research.14227.2 |
_version_ | 1783386155952111616 |
---|---|
author | Bullerdiek, Jörn Rommel, Birgit |
author_facet | Bullerdiek, Jörn Rommel, Birgit |
author_sort | Bullerdiek, Jörn |
collection | PubMed |
description | Mediator Complex Subunit 12 (MED12) is part of the transcriptional preinitiation machinery. Mutations of its gene predominantly occur in two types of highly frequent benign tumors, uterine leiomyomas and fibroadenomas of the breast, where they apparently act as driver mutations. Nevertheless, their presence is not restricted to benign tumors having been found at considerable frequencies in uterine leiomyosarcomas, malignant phyllodes tumors, and chronic lymphocytic leukemia also. Most of the mutations are located within exon 2 of the gene but in rare cases the intron 1/exon 2 boundary or exon 1 are affected. As to their type, predominantly single nucleotide exchanges with a hotspot in one codon are found, but small deletions clustering around that hotspot also are not uncommon. These latter deletions are leaving the open reading frame intact. As to the types of mutations, so far no apparent differences between the tumor entities affected have emerged. Interestingly, this pattern with small deletions clustered around the hotspot of single nucleotide exchanges resembles that seen as a result of targeted gene editing. In contrast to other driver mutations the percentage of MED12-mutation positive tumors of independent clonal origin increases with the number of tumors per patient suggesting unknown etiological factors supporting site specific mutagenesis. These factors may act by inducing simultaneous site-specific double strand breaks the erroneous repair of which may lead to corresponding mutations. As inducers of DNA damage and its repair such as foreign nucleic acids of the microbiome displaying sequence homology to the putative target site might play a role. Interestingly, a 16 base pair homology of the hotspot to a putative terminator base-paired hairpin sequence of a Staphylococcus aureus tRNA gene cluster has been noted which might form R-loop like structures with its target sequence thus inducing said changes. |
format | Online Article Text |
id | pubmed-6325618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-63256182019-01-14 Factors targeting MED12 to drive tumorigenesis? Bullerdiek, Jörn Rommel, Birgit F1000Res Opinion Article Mediator Complex Subunit 12 (MED12) is part of the transcriptional preinitiation machinery. Mutations of its gene predominantly occur in two types of highly frequent benign tumors, uterine leiomyomas and fibroadenomas of the breast, where they apparently act as driver mutations. Nevertheless, their presence is not restricted to benign tumors having been found at considerable frequencies in uterine leiomyosarcomas, malignant phyllodes tumors, and chronic lymphocytic leukemia also. Most of the mutations are located within exon 2 of the gene but in rare cases the intron 1/exon 2 boundary or exon 1 are affected. As to their type, predominantly single nucleotide exchanges with a hotspot in one codon are found, but small deletions clustering around that hotspot also are not uncommon. These latter deletions are leaving the open reading frame intact. As to the types of mutations, so far no apparent differences between the tumor entities affected have emerged. Interestingly, this pattern with small deletions clustered around the hotspot of single nucleotide exchanges resembles that seen as a result of targeted gene editing. In contrast to other driver mutations the percentage of MED12-mutation positive tumors of independent clonal origin increases with the number of tumors per patient suggesting unknown etiological factors supporting site specific mutagenesis. These factors may act by inducing simultaneous site-specific double strand breaks the erroneous repair of which may lead to corresponding mutations. As inducers of DNA damage and its repair such as foreign nucleic acids of the microbiome displaying sequence homology to the putative target site might play a role. Interestingly, a 16 base pair homology of the hotspot to a putative terminator base-paired hairpin sequence of a Staphylococcus aureus tRNA gene cluster has been noted which might form R-loop like structures with its target sequence thus inducing said changes. F1000 Research Limited 2018-12-13 /pmc/articles/PMC6325618/ /pubmed/30647905 http://dx.doi.org/10.12688/f1000research.14227.2 Text en Copyright: © 2018 Bullerdiek J and Rommel B http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Opinion Article Bullerdiek, Jörn Rommel, Birgit Factors targeting MED12 to drive tumorigenesis? |
title | Factors targeting
MED12 to drive tumorigenesis? |
title_full | Factors targeting
MED12 to drive tumorigenesis? |
title_fullStr | Factors targeting
MED12 to drive tumorigenesis? |
title_full_unstemmed | Factors targeting
MED12 to drive tumorigenesis? |
title_short | Factors targeting
MED12 to drive tumorigenesis? |
title_sort | factors targeting
med12 to drive tumorigenesis? |
topic | Opinion Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325618/ https://www.ncbi.nlm.nih.gov/pubmed/30647905 http://dx.doi.org/10.12688/f1000research.14227.2 |
work_keys_str_mv | AT bullerdiekjorn factorstargetingmed12todrivetumorigenesis AT rommelbirgit factorstargetingmed12todrivetumorigenesis |